The PostEra crew (L-R); technology chief Matthew Robinson, CEO Aaron Morris and CSO Alpha Lee

January 7, 2025 11:10 AM EST

Pfizer extends AI drug discovery pact with PostEra, adding ADCs to deal

Lei Lei Wu

News Reporter

Pfizer has re-upped its drug discovery deal with AI startup PostEra to develop small molecule drugs and new warheads for antibody-drug conjugates, a major area …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer extends AI drug discovery pact with PostEra, adding ADCs to deal

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Galapagos to split into two companies, slash headcount as it eyes turnaround

Maze files for first biotech IPO of 2025, following $115M funding boost

Novo expands pact with Flagship's Valo to include obesity, diabetes for $190M near-term

FDA sets an efficacy threshold for future weight loss drugs

With schizophrenia trial success, LB Pharmaceuticals thinks about Phase 3 and next funding

J&J's new cancer combo beats AstraZeneca's Tagrisso on survival in lung trial

Pfiz­er ex­tends AI drug dis­cov­ery pact with PostEra, adding AD­Cs to deal

Lei Lei Wu

News Reporter

Sign up to read this article for free.

more like this

Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

No­vo ex­pands pact with Flag­ship's Va­lo to in­clude obe­si­ty, di­a­betes for $190M near-term

FDA sets an ef­fi­ca­cy thresh­old for fu­ture weight loss drugs

With schiz­o­phre­nia tri­al suc­cess, LB Phar­ma­ceu­ti­cals thinks about Phase 3 and next fund­ing

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

Pfizer extends AI drug discovery pact with PostEra, adding ADCs to deal

Galapagos to split into two companies, slash headcount as it eyes turnaround

Maze files for first biotech IPO of 2025, following $115M funding boost

Novo expands pact with Flagship's Valo to include obesity, diabetes for $190M near-term

FDA sets an efficacy threshold for future weight loss drugs

With schizophrenia trial success, LB Pharmaceuticals thinks about Phase 3 and next funding

J&J's new cancer combo beats AstraZeneca's Tagrisso on survival in lung trial